DrugPatentWatch Database Preview

Ranibizumab - Biologic Drug Details

Email this page to a colleague

« Back to Dashboard

Summary for ranibizumab

Tradenames:	1
Patents:	235
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for ranibizumab
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ranibizumab

Recent Clinical Trials for ranibizumab

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Uptown Eye Specialists	N/A
Shanghai Henlius Biotech	Phase 3
Faculty Hospital Kralovske Vinohrady	Phase 4

See all ranibizumab clinical trials

Recent Litigation for ranibizumab

Identify key patents and potential future biosimilar entrants

District Court Litigation

Case Name	Date
Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc.	2020-06-19

See all ranibizumab litigation

PTAB Litigation

Petitioner	Date
Regeneron Pharmaceuticals, Inc.	2021-04-16
Regeneron Pharmaceuticals, Inc.	2020-07-16

See all ranibizumab litigation

Pharmacology for ranibizumab

Mechanism of Action

Vascular Endothelial Growth Factor Receptor Inhibitors Vascular Endothelial Growth Factor-directed Antibody Interactions

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ranibizumab Derived from Brand-Side Litigation

These patents were extracted from brand-side disclosures in response to biosimilar applications

BLA	Patent No.	Expiration Date
125156		2034-03-14
125156		2035-11-05
125156		2033-09-19
125156		2034-03-14
125156		2021-11-01
125156		2022-07-08

2) High Certainty: US Patents for ranibizumab Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for ranibizumab Derived from Patent Text Search

These patents were identified by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30			2039-03-29	RX		search
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30		Innfocus, LLC (Miami, FL)	2024-12-03	RX		search
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30		Genentech, Inc. (South San Francisco, CA)	2025-05-20	RX		search
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30		Neurotech USA, Inc. (Lincoln, RI)	2025-12-30	RX		search
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30		Innfocus, LLC (Miami, FL)	2024-12-03	RX		search
Genentech	LUCENTIS	ranibizumab	INJECTABLE; INJECTION	125156	001	2006-06-30		Bioresponse, L.L.C. (Boulder, CO)	2024-12-30	RX		search

International Patents for ranibizumab

Country	Patent Number	Estimated Expiration
Japan	2013544881
Japan	2007535536
World Intellectual Property Organization (WIPO)	2004034977
South Korea	20150067388
World Intellectual Property Organization (WIPO)	2012028733
European Patent Office	2611414